ACADIA Pharmaceuticals (NASDAQ:ACAD) Lowered to Hold Rating by StockNews.com

StockNews.com lowered shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) from a buy rating to a hold rating in a research note released on Friday.

A number of other research analysts also recently weighed in on ACAD. Cantor Fitzgerald restated an “overweight” rating and set a $28.00 price target on shares of ACADIA Pharmaceuticals in a report on Thursday. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 target price on shares of ACADIA Pharmaceuticals in a report on Thursday. HC Wainwright reiterated a “buy” rating and issued a $27.00 target price on shares of ACADIA Pharmaceuticals in a report on Thursday. Deutsche Bank Aktiengesellschaft started coverage on shares of ACADIA Pharmaceuticals in a report on Tuesday, February 11th. They issued a “hold” rating and a $22.00 target price on the stock. Finally, Guggenheim downgraded shares of ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $23.00 to $20.00 in a report on Friday, January 3rd. Nine research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $24.00.

ACADIA Pharmaceuticals Trading Up 1.3 %

ACADIA Pharmaceuticals stock opened at $19.60 on Friday. The company has a market capitalization of $3.26 billion, a P/E ratio of 25.13 and a beta of 0.37. The firm’s fifty day simple moving average is $18.37 and its 200-day simple moving average is $16.81. ACADIA Pharmaceuticals has a 1-year low of $14.15 and a 1-year high of $24.53.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Virtus Fund Advisers LLC bought a new position in shares of ACADIA Pharmaceuticals during the 4th quarter worth about $39,000. R Squared Ltd acquired a new stake in shares of ACADIA Pharmaceuticals during the 4th quarter valued at about $47,000. GF Fund Management CO. LTD. acquired a new stake in shares of ACADIA Pharmaceuticals during the 4th quarter valued at about $64,000. Quest Partners LLC boosted its position in shares of ACADIA Pharmaceuticals by 42.3% during the 3rd quarter. Quest Partners LLC now owns 3,520 shares of the biopharmaceutical company’s stock valued at $54,000 after acquiring an additional 1,047 shares in the last quarter. Finally, KBC Group NV boosted its position in shares of ACADIA Pharmaceuticals by 67.0% during the 4th quarter. KBC Group NV now owns 5,093 shares of the biopharmaceutical company’s stock valued at $93,000 after acquiring an additional 2,044 shares in the last quarter. Institutional investors own 96.71% of the company’s stock.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.